Teriparatide injection, used to treat osteoporosis, has a varied cost that can depend on factors such as dosage, quantity, and insurance coverage. For example, a 2.4 mL vial of 20 mcg/0.8 mL solution is often priced around $300, though this figure can fluctuate [1].
What determines the price of Teriparatide?
The list price for teriparatide injections can range significantly. One common presentation, a 2.4 mL vial containing 20 mcg/0.8 mL of the solution, is frequently listed at approximately $300 [1]. However, the actual out-of-pocket expense for patients can be much lower due to insurance plans, patient assistance programs, and pharmacy discounts [1]. The dosage and the number of units prescribed also directly influence the total cost.
Are there different forms of Teriparatide available?
Teriparatide is available in injectable forms, typically administered daily. The common presentation is a pre-filled pen or a vial, with specific concentrations and volumes designed for treatment [1].
How does insurance affect Teriparatide costs?
Insurance coverage plays a crucial role in the final cost of teriparatide injections. Many insurance plans cover a portion of the prescription, reducing the patient's copay or deductible. Patients are advised to check their specific insurance policy or contact their provider to understand their coverage details and potential out-of-pocket expenses [1].
Are there patient assistance programs for Teriparatide?
Pharmaceutical manufacturers often provide patient assistance programs to help eligible individuals afford their medications. These programs can offer copay cards, discounts, or even free medication for those who meet certain financial criteria [1]. Information about such programs is usually available through the drug manufacturer's website or by asking a healthcare provider.
When do Teriparatide patents expire?
The patent landscape for teriparatide is complex, with multiple patents covering the drug substance, methods of use, and formulations. For instance, certain patents associated with teriparatide have expired or are nearing expiration, which could pave the way for generic or biosimilar versions. DrugPatentWatch.com tracks these patent expirations and provides detailed information on intellectual property for various drugs [2].
Who manufactures Teriparatide?
Teriparatide is manufactured by several pharmaceutical companies. Original formulations were developed by companies like Eli Lilly and Company, but as patents expire, other companies begin producing generic versions. Biosimilar versions may also be available from different manufacturers [2].
What are the alternatives to Teriparatide for osteoporosis treatment?
Besides teriparatide, other medications are available for treating osteoporosis. These include bisphosphonates (e.g., alendronate, risedronate), denosumab, raloxifene, and estrogen therapy. The choice of treatment depends on individual patient factors, including bone density, fracture history, and other medical conditions [3].
How does Teriparatide work?
Teriparatide is a form of parathyroid hormone. It works by stimulating bone formation, increasing bone mineral density, and reducing the risk of fractures. It is typically prescribed for individuals with a high risk of fracture or who have not responded to other osteoporosis treatments [3].
What are the potential side effects of Teriparatide?
Common side effects of teriparatide injections include nausea, joint pain, headache, and dizziness. Less common but more serious side effects can occur, and patients should discuss any concerns with their healthcare provider [3].
Sources:
[1] https://www.goodrx.com/teriparatide
[2] https://drugpatentwatch.com/
[3] https://www.mayoclinic.org/diseases-conditions/osteoporosis/diagnosis-treatment/drc-20350873